CS-1008 + Paclitaxel + Carboplatin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer Stage IIIC
Conditions
Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Trial Timeline
Oct 6, 2009 → Aug 23, 2011
NCT ID
NCT00945191About CS-1008 + Paclitaxel + Carboplatin
CS-1008 + Paclitaxel + Carboplatin is a phase 2 stage product being developed by Daiichi Sankyo for Ovarian Cancer Stage IIIC. The current trial status is completed. This product is registered under clinical trial identifier NCT00945191. Target conditions include Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Cancer Stage IIIC were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00945191 | Phase 2 | Completed |
Competing Products
20 competing products in Ovarian Cancer Stage IIIC